Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for

Related Keywords

Germany ,United States ,Paris ,France General ,France ,Denmark ,Munich ,Bayern ,United Kingdom ,Belgium ,Switzerland ,German ,Assia Mouhout ,Kostenloser Wertpapierhandel ,Andreas Wallnoefer ,Bayern Kapital ,Phil Lhuillier ,Marion Bougeard ,Linkedin ,Twitter ,Trophic Communications ,Novartis Venture Fund ,Jeito Capital ,Brandon Capital ,Vesalius Biocapital ,Biogeneration Ventures ,Growth Differentiation ,Ted Human Effector ,Relocation Phase ,European Biopharma ,Phill Huillier ,Chief Executive Officer ,Strategic Communications Mary Jane Elliott ,Davide Salvi ,Jeito ,Capital ,Heads ,Billion ,Financing ,Catalym ,Linical ,Stage ,Iopharma ,Company ,Developing ,Novel ,Mmunotherapies ,Patients ,Dancer ,